JMT106 for advanced solid tumors
Part of Cancer, Digestive system clinical trials.
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor (cancer that has spread or can't be removed) that hasn't responded to or cannot use standard treatments.
- You must be 18 years or older and in fairly good physical condition (able to do daily activities, like walking and light work).
- Your cancer has not been treated with a drug that targets GPC3 (a specific protein some cancers have).
- You have at least one tumor that can be measured on a scan, and you are expected to live at least 3 more months.
- Your blood counts, kidney function, and liver function must be within certain limits (checked through lab tests).
- You cannot have untreated or active brain tumors, or be on strong immune-suppressing medications like high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called JH021 in people with advanced solid tumors or a specific type of lung cancer. The goal is to see if it can help when other treatments have stopped working.
This trial tests a new drug called JMT108 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to see if the drug is safe and how it affects the body.
This trial tests a new drug called JMT108 for people with advanced solid tumors that haven't responded to standard treatments. It aims to find out if the drug is safe and how well it works against cancer.
This study tests a new drug called JMT108 for advanced melanoma or urinary tract cancer. It may help your immune system attack the cancer, and the study is checking if it is safe and how well it works.
This trial tests a new experimental drug for people with advanced solid tumors that have not responded to standard treatments. It aims to find a safe dose and see if the drug can shrink tumors.
This is an early-stage trial testing a new cancer treatment called JLM019 in patients with advanced solid tumors or lymphomas that haven't responded to other treatments. The study aims to find the right dose and see how well the drug works and how patients tolerate it.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.